Amgen's $650M Boost: New Jobs and Biosimilar Shift
Update: 2025-10-01
Description
Amgen's stock price surged almost six percent after announcing a $650 million U.S. manufacturing expansion in Puerto Rico, creating 750 jobs. The jump follows rumors of a potential White House drug pricing agreement and a settlement allowing Biocon to launch a biosimilar version of Amgen's denosumab drug in 2025. Is this a turning point for Amgen and the future of biomanufacturing?
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
